---
title: "CUTIA-B shareholders transferred their shares from Citibank to Morgan Stanley Hong Kong Securities, with a transfer value of HKD 122 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/273765997.md"
description: "According to the latest information from the Hong Kong Stock Exchange, on January 26, CUTIA-B shareholders transferred their shares from Citibank to Morgan Stanley Hong Kong Securities, with a transfer market value of HKD 122 million, accounting for 7.07%. Previously, CUTIA-B announced that its CU-20101 (injectable type A botulinum toxin) for the treatment of moderate to severe glabellar lines achieved positive top-line results in its Phase III clinical trial in China"
datetime: "2026-01-27T00:57:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273765997.md)
  - [en](https://longbridge.com/en/news/273765997.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273765997.md)
---

# CUTIA-B shareholders transferred their shares from Citibank to Morgan Stanley Hong Kong Securities, with a transfer value of HKD 122 million

According to the latest information from the Hong Kong Stock Exchange, on January 26, CUTIA-B (02487) shareholders transferred their shares from Citibank to Morgan Stanley Hong Kong Securities, with a transfer market value of HKD 122 million, accounting for 7.07%.

Previously, CUTIA-B announced that its CU-20101 (injectable type A botulinum toxin) for the treatment of moderate to severe glabellar lines achieved positive top-line results in a Phase III clinical trial in China

### Related Stocks

- [159892.CN](https://longbridge.com/en/quote/159892.CN.md)
- [159506.CN](https://longbridge.com/en/quote/159506.CN.md)
- [513700.CN](https://longbridge.com/en/quote/513700.CN.md)
- [520690.CN](https://longbridge.com/en/quote/520690.CN.md)
- [02487.HK](https://longbridge.com/en/quote/02487.HK.md)
- [159316.CN](https://longbridge.com/en/quote/159316.CN.md)
- [520880.CN](https://longbridge.com/en/quote/520880.CN.md)

## Related News & Research

- [China’s Clinical Trial Registrations Surpass 5,000 for First Time in 2025](https://longbridge.com/en/news/290539713.md)
- [Cutia Therapeutics AGM resolutions passed in shareholder vote](https://longbridge.com/en/news/290935117.md)
- [Shandong Xinhua Pharma wins China approval to start LXH-2103 pain drug clinical trials](https://longbridge.com/en/news/290406287.md)
- [DFTX: DT120 ODT achieved rapid, robust, and durable efficacy in MDD with strong safety in Phase 3](https://longbridge.com/en/news/290425492.md)
- [Kymera Therapeutics completes enrollment in Phase 2b BROADEN2 trial of KT-621 for atopic dermatitis](https://longbridge.com/en/news/290819796.md)